Dakshina. M. Nair

Dakshina. M. Nair

Auto-generated profile, based on publicly available information

Dakshina. M. Nair

Department of Microbiology, SRM Medical Hospital and Research Center, SRM Institute of Science and Technology, Kattakulanthur, Chengalpattu, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
RLRahul Harikumar Lathakumari
Rahul Harikumar Lathakumari
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
JTJayaprakash Thulukanam
Jayaprakash Thulukanam
DNDakshina M. Nair
Dakshina M. Nair
PVPoornima Baskar Vimala
Poornima Baskar Vimala
VPVishnupriya Panneerselvam
Vishnupriya Panneerselvam
Background: Carbapenem-resistant Gram-negative bacteria (CR-GNB) pose a serious global health threat, especially in low- and middle-income countries. Local surveillance is crucial for informing antimicrobial stewardship and infection control strategies. This study aimed to evaluate the prevalence, demographic distribution, and temporal fluctuations of carbapenem resistance among key Gram-negative pathogens in a South Indian tertiary care center over a two-year period.Methods: A retrospective study was conducted on 8,359 non-duplicate Gram-negative isolates obtained from clinical specimens between July 2022 and July 2024. Organisms were identified, and antimicrobial susceptibility was determined using the VITEK® 2 Compact system (BioMérieux). Resistance to imipenem (IPM) and meropenem (MEM) was assessed. Data were stratified by age, sex, ward type, specimen source, and quarterly distribution. A subset of resistant isolates underwent molecular screening for carbapenemase genes using real time PCR.Results: Carbapenem resistance was observed in 24% (2007) of Gram-negative isolates. Acinetobacter baumannii (48.0%) and Klebsiella pneumoniae (38.6%) accounted for the majority of resistant cases. Resistance was significantly higher in males (64.3%) and in patients aged 61–80 years (p < 0.001). Surgical wards showed greater resistance rates compared to medical departments. A peak in resistance was identified during January–March 2023, particularly for A. baumannii (76.3%). IPM-MEM resistance discrepancies were found in Citrobacter and Proteus species. Gene profiling of resistant strains revealed the predominance of blaNDM, blaVIM in all organism.Conclusion: The findings reveal a high and fluctuating burden of carbapenem resistance, especially in elderly males and surgical settings. Continuous surveillance and targeted interventions are vital to curbing the spread of CR-GNB in high-risk healthcare environments.

28 August 2024 in Virus Genes
Verified
Journal Article
Closed access
PDF file
DNDakshina M. Nair
Dakshina M. Nair
LVLeela Kakithakara Vajravelu
Leela Kakithakara Vajravelu
JTJayaprakash Thulukanam
Jayaprakash Thulukanam
VPVishnupriya Paneerselvam
Vishnupriya Paneerselvam
PVPoornima Baskar Vimala
Poornima Baskar Vimala
RLRahul Harikumar Lathakumari
Rahul Harikumar Lathakumari

1 January 2026 in Gastroenterology & Endoscopy
Verified
Journal Article
Open access
DNDakshina M. Nair
Dakshina M. Nair
LVLeela Kakithakara Vajravelu
Leela Kakithakara Vajravelu
PVPoornima Baskar Vimala
Poornima Baskar Vimala
RLRahul Harikumar Lathakumari
Rahul Harikumar Lathakumari
VPVishnupriya Paneerselvam
Vishnupriya Paneerselvam
JTJayaprakash Thulukanam
Jayaprakash Thulukanam

13 November 2024 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
AYAlankritha Yadhunandan
Alankritha Yadhunandan
RSR. Sujith Sri Surya
R. Sujith Sri Surya
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
BVBalamurali Venkatesan
Balamurali Venkatesan
PDP. Deeksha
P. Deeksha
DNDakshina M. Nair
Dakshina M. Nair
In rural communities, the blaNDM-1 gene in the gut microbiota may be contributing to the growing issue of antibiotic resistance. This gene enables bacteria to produce enzymes that break down antibiotics, making treatments less effective. The limited healthcare resources and frequent exposure to resistant bacteria in these areas could further amplify this problem, increasing the risk of difficult-to-treat infections among the population. The objective of this study was to evaluate the antimicrobial susceptibility of Escherichia coli [E. coli] strains isolated from healthy individuals and to assess the prevalence of blaNDM-1 gene carriage. The samples were cultured and identified as gut commensal by conventional method. Then antibiotic susceptibility test using the Kirby Bauer disc diffusion method were carried out. Carbapenem-resistant organisms were isolated, and the blaNDM-1 was identified by polymerase chain reaction. This study includes 187 Healthy participants faecal samples were obtained from people in and around the Chengalpattu area. Out of 187 samples, 110 showed E. coli growth, 63 showed Enterococci species growth, and 14 showed no growth. Among the 110 E. coli isolates, 24 (21.8%) were sensitive to all drug classes, and 86 (78.2%) were multidrug resistant. Only 8(7.27%) of the 110 E. coli tested positive for carbapenem resistance. Out of 110 E. coli isolates, only (2.7%) had the blaNDM-1 gene. This study discovered that rural communities that are unlikely to be subjected to obvious antibiotic pressure had a high incidence of MDR microorganism faecal carriage. Finding resistance genes in commensal bacteria is alarming. This has the ability to spread and emerge in the environment.

10 November 2025 in International Journal of Current Microbiology and Applied Sciences
Verified
Journal Article
Closed access
DNDakshina M. Nair
Dakshina M. Nair
LVLeela Kakithakara Vajravelu
Leela Kakithakara Vajravelu
RSR. Sujith Sri Surya
R. Sujith Sri Surya
PDP. Deeksha
P. Deeksha
AYAlankritha Yadhunandhan
Alankritha Yadhunandhan
Vulvovaginal candidiasis (VVC) affects up to 75% of women worldwide, with recurrent episodes posing significant clinical and psychosocial challenges. While Candida albicans remains the predominant pathogen, Candida non-albicans species are increasingly reported and frequently exhibit antifungal resistance. Biofilm formation further complicates treatment, conferring enhanced tolerance to antifungal agents. This study investigated the species distribution, antifungal susceptibility, biofilm production, and the potential synergistic effect of fluconazole–gentamicin combination therapy against Candida isolates from VVC. A total of 120 vaginal Candida isolates from women aged 18–40 years were collected over eight months (June 2022–January 2023). Identification was performed using conventional mycological methods and CHROMagar. Antifungal susceptibility testing followed CLSI guidelines. Biofilm formation was assessed by microtiter plate assay, and minimum inhibitory concentrations (MICs) of fluconazole, gentamicin, and their combination were determined using broth microdilution. Candida albicans accounted for 35% of isolates, followed by C. parapsilosis (30%), C. glabrata (15%), C. krusei (11%), and C. tropicalis (9%). Fluconazole resistance was observed in 14.1% (17/120) of isolates, the majority of which 13 (76.4%) were strong biofilm producers. Combination therapy with fluconazole–gentamicin demonstrated a marked reduction in MIC values, with 84.6% (11/13) of resistant isolates showing restored susceptibility (MIC ≤ 2 μg/mL), compared to fluconazole or gentamicin monotherapy. Our findings suggest that fluconazole–gentamicin combination therapy exhibits promising synergistic activity against fluconazole-resistant Candida isolates, highlighting a potential alternative strategy for difficult-to-treat VVC cases.

16 May 2026 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
PVPoornima Baskar Vimala
Poornima Baskar Vimala
KLKakithakara Vajravelu Leela
Kakithakara Vajravelu Leela
VPVishnu Priya Panneerselvam
Vishnu Priya Panneerselvam
DNDakshina M Nair
Dakshina M Nair
RLRahul Harikumar Lathakumari
Rahul Harikumar Lathakumari
JTJayaprakash Thulukanam
Jayaprakash Thulukanam
Epithelial-mesenchymal transition (EMT) is a fundamental driver of cancer invasion, metastasis, and therapeutic resistance, mediated by dynamic switching between E-cadherin (CDH1) and N-cadherin (CDH2). Although cadherins are central regulators of EMT, current therapeutic strategies rarely exploit EMT-state-specific cadherin dependencies. In this study, we present a structure-driven, EMT-aware computational framework to repurpose and engineer colicins as cadherin-selective anti-metastatic biologics. Pan-cancer transcriptomic profiling across thirty-three tumor types revealed distinct CDH1- and CDH2-dominant EMT landscapes, providing a rational basis for receptor-informed targeting. stereo chemically validated structures of Colicin E1 and Colicin E2 were subjected to stability-guided mutagenesis using FoldX, followed by protein-protein docking and atomistic molecular dynamics simulations with E- and N-cadherin. Docking analyses demonstrated intrinsic cadherin preferences, with Colicin E2 exhibiting stronger affinity for CDH1 and Colicin E1 favouring CDH2, mirroring EMT-associated cadherin switching. Molecular dynamics simulations further confirmed these trends, revealing stable complex formation, reduced backbone deviation, sustained interfacial contacts, and distinct residue-level flexibility profiles in preferred colicin-cadherin pairs. Structure-guided mutations significantly enhanced binding stability and specificity, identifying Colicin E2 mutant A579E as the most optimized variant, characterized by improved docking scores, reduced conformational fluctuations, and persistent E-cadherin engagement throughout simulations. Compared with prior EMT-targeting approaches, this work uniquely integrates transcriptomic context with structure-guided protein engineering to achieve cadherin-state selectivity rather than broad inhibition. Collectively, this study establishes a novel computational paradigm for EMT-state-guided biologic design and provides a predictive foundation for future experimental validation, cadherin-resolved cancer stratification, and translational development of precision anti-metastatic protein therapeutics in diverse solid tumor contexts clinically.